Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 12/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 2/20 | 0.35 |
| ▸ | CCR9 | P51686 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17678702 | 0.90 | OGA (0.38) | OGAVNN1OPRK1 | |
| SCHEMBL19699776 | 0.87 | DHODH (0.39) | OGAOPRK1DHODH | |
| SCHEMBL17674213 | 0.84 | ALOX15 (0.43) | PIK3CAOPRK1 | |
| SCHEMBL17845850 | 0.84 | VNN1 (0.40) | VNN1OPRK1CCR9 | |
| SCHEMBL20598038 | 0.83 | SCN10A (0.42) | — | |
| SCHEMBL17675419 | 0.81 | OPRK1 (0.36) | OPRK1DHODH | |
| SCHEMBL19454416 | 0.80 | VNN1 (0.33) | VNN1OPRK1 | |
| SCHEMBL20618190 | 0.80 | ABCC1 (0.37) | VNN1PIK3CAOPRK1 | |
| SCHEMBL20598200 | 0.80 | DHODH (0.42) | OGAPIK3CAOPRK1DHODH | |
| SCHEMBL19151000 | 0.79 | OGA (0.34) | OGAVNN1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11534439-B2 | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11534439-B2 | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220016112-A1 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2022-01-20 | — | — | US | disclosed |
| US-20220016112-A1 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2022-01-20 | — | — | US | disclosed |
| WO-2022010882-A1 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC, (US) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022010882-A1 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC, (US) | 2022-01-13 | — | — | WO | disclosed |
| US-11179400-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11179400-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-9732098-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative | PULMOCIDE LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-9732098-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative | PULMOCIDE LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-9732098-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative | PULMOCIDE LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-20170190718-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVE | AKLIEBOLAGET SKF (SE) | 2017-07-06 | — | — | US | disclosed |
| US-20170190718-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVE | AKLIEBOLAGET SKF (SE) | 2017-07-06 | — | — | US | disclosed |
| US-20170190718-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVE | AKLIEBOLAGET SKF (SE) | 2017-07-06 | — | — | US | disclosed |
| WO-2016055792-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055791-A1 | Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative | PULMOCIDE LIMITED (GB) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055791-A1 | Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative | PULMOCIDE LIMITED (GB) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055792-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190718-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVE | ZC3HAV1, HYOU1, DHX15 | OGA 4860/4885VNN1 612/4885PIK3CA 4487/4885 |
| US-11534439-B2 | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors | SIRT5, QDPR, NOX5 | OGA 4260/4885VNN1 1334/4885PIK3CA 1675/4885 |
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | OGA 4482/4885VNN1 755/4885PIK3CA 1143/4885 |
| US-11179400-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | OGA 4482/4885VNN1 755/4885PIK3CA 1143/4885 |
| US-20220016112-A1 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS | SIRT5, QDPR, NOX5 | OGA 4260/4885VNN1 1334/4885PIK3CA 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.